Provide feedbackProvide feedback

Home :: Neurology :: Alzheimer's Disease & Dementia

NIH, Banner Alzheimer's Institute, Genentech collaborate to evaluate crenezumab in prevention of AD

Wednesday, May 16 2012 | Comments
Evidence Grade 0 What's This?

The National Institutes of Health, the Banner Alzheimer's Institute, Genentech Inc. and the University of Antioquia in Colombia are collaborating on the first trial to evaluate a drug in the prevention of Alzheimer's disease (AD) among cognitively healthy individuals with a genetic risk of developing AD. The $100 million trial is the cornerstone of the Alzheimer's Prevention Initiative, a new international collaborative effort to accelerate the evaluation of promising but unproven...

The National Institutes of Health, the Banner Alzheimer's Institute, Genentech Inc. and the University of Antioquia in Colombia are collaborating on the first trial to evaluate a drug in the prevention of Alzheimer's disease (AD) among cognitively healthy individuals with a genetic risk of developing AD.

The $100 million trial is the cornerstone of the Alzheimer's Prevention Initiative, a new international collaborative effort to accelerate the evaluation of promising but unproven therapies for the prevention of AD.

The double-blind trial will evaluate crenezumab, an investigational anti-amyloid antibody, in approximately 300 people from a large extended family in Colombia who share a rare genetic mutation that typically triggers AD symptom onset at approximately age 45 years. The drug will also be evaluated in a smaller number of individuals in the United States. All participants will be aged 30 years or older with normal cognitive function at enrollment.

To avoid revealing the genetic status of the participants, most of whom do not want to know if they have the genetic mutation that increases their AD risk, the study will also include relatives who are noncarriers who will receive placebo.

The participants will receive injections of crenezumab or placebo at fixed intervals for up to five years. Researchers will use imaging techniques, cerebrospinal fluid tests and cognitive measures to monitor whether accumulation of amyloid and certain other proteins in the brain is reduced, whether brain size and function is maintained and whether mental performance is preserved.

The study will test the "amyloid hypothesis," which suggests that accumulation of the amyloid protein in the brain plays a key role in the progression of AD. Preclinical data indicate that crenezumab works by binding amyloid proteins and clearing them from the brain.

Genentech will contribute the majority of the funding for the trial, in addition to providing the study drug, as well as clinical and operational expertise.

Crenezumab is also currently being evaluated in a Phase II trial of patients with mild to moderate AD symptoms. The drug was selected for use in the prevention trial with guidance from an expert advisory panel.

Genentech is developing crenezumab in collaboration with Swiss biotech company AC Immune SA.

Latest News

AstraZeneca, MedImmune collaborate with Axerion on biologic approach for AD Verusmed

Wednesday, May 02 2012 | Comments
Evidence Grade 0 What's This?

MedImmune LLC, the biologics unit of AstraZeneca Plc, entered into a research collaboration and sublicense agreement with Axerion Therapeutics Inc., a privately held biotechnology firm based in Connecticut, to develop and commercialize a biologic approach to the treatment of Alzheimer's disease (AD).

Under the terms of the agreement,...

Tags: Alzheimer's Disease & Dementia


Eisai, Teikoku Pharma revise Aricept patch license agreement Verusmed

Friday, April 20 2012 | Comments
Evidence Grade 0 What's This?

Eisai Co. Ltd. amended its licensing agreement with Teikoku Pharma USA Inc. regarding the marketing rights for the once-weekly, transdermal patch formulation of Eisai's Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease (AD).

The companies established the original agreement, which covered development and commercialization rights in all territories other than...

Tags: Alzheimer's Disease & Dementia


Bayer sells molecular imaging development portfolio to Piramal Healthcare Verusmed

Monday, April 16 2012 | Comments
Evidence Grade 0 What's This?

Bayer AG sold the worldwide rights to its molecular imaging research and development portfolio to India-based Piramal Healthcare Ltd.

The transaction includes the development, marketing and distribution rights to florbetaben, a positron emission tomography (PET) imaging agent for the detection of beta-amyloid plaques in the brain that is in...

Tags: Alzheimer's Disease & Dementia


GE Healthcare forms research collaboration with Japanese biotechnology firm to develop AD imaging agents Verusmed

Sunday, April 15 2012 | Comments
Evidence Grade 0 What's This?

GE Healthcare's medical diagnostics division entered into a research collaboration with Clino Ltd., a biotechnology venture of Tohoku University, to develop positron emission tomography (PET) imaging agents for the detection of tau proteins.

It is thought that Alzheimer's disease (AD) is caused by the accumulation in the...

Tags: Alzheimer's Disease & Dementia




Neurology Conference Coverage
  1. No articles have been read
  1. No articles have been emailed
Videos